Transcript
I'm David Carbone. I'm a thoracic medical oncologist and the Director of the Thoracic Oncology Center at Ohio State University in Columbus, Ohio. I would like to talk today a little bit about some of the recent progress in lung cancer.
The next abstract is from MGH. It's first author Dagogo-Jack. It's a phase 2 study of lorlatinib in patients with brain-only progression. ALK fusion-positive diseases have a very high tendency to develop brain metastases and intracranial activity is especially important.
When it was initially treated with crizotinib, >50% of the patients ended up progressing in the brain. Alectinib is better at that, but the others, brigatinib and lorlatinib, also have efficacy.
In this study, they looked at 22 patients that had progressed on prior ALK-TKIs with brain-only progression. They treated them with lorlatinib, and they showed that the intracranial objective response rate in that setting was 59%, and the disease control rate was nearly 100%, 93%.
That emphasizes that you can effectively switch TKIs from one to another and that even after progression on alectinib, you can get intracranial benefit from switching to lorlatinib.
The next study is from the IFCT. The first author is Baldacci. They looked at, again, lorlatinib in an expanded access cohort. They had data from the French registry. There were approximately 200 patients included in the study, 143 without and 57 with ROS.
In this study, they showed that all of these patients had previous TKIs, but when they started on and progressed on those TKIs, the objective response rate in this study for ALK fusion-positive disease was 46%, with an 86% disease control rate, and very durable responses in the ALK-positive cohort.
The median survival had not even been reached, and many patients were out close to 2 and 3 years with high efficacy.
